Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Carvedilol Post-intervention Long-term Administration in Large-scale Trial (CAPITAL-RCT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeshi Morimoto, Kyoto University, Graduate School of Medicine
ClinicalTrials.gov Identifier:
NCT01155635
First received: July 1, 2010
Last updated: January 5, 2016
Last verified: December 2015
  Purpose
The purpose of this study is to evaluate whether beta-blocker therapy improves 6-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction and preserved left ventricular ejection fraction after primary percutaneous coronary intervention.

Condition Intervention Phase
Myocardial Infarction
Drug: Carvedilol
Drug: No Carvedilol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Kyoto University, Graduate School of Medicine:

Primary Outcome Measures:
  • All cause mortality [ Time Frame: 6-year ]
    Death from any reason

  • Composite of death, myocardial infarction, acute coronary syndrome, heart failure hospitalization [ Time Frame: 6-year ]

Secondary Outcome Measures:
  • Cardiac death [ Time Frame: 6-year ]
  • Sudden cardiac death [ Time Frame: 6-year ]
  • Cardiovascular death [ Time Frame: 6-year ]
  • Myocardial infarction [ Time Frame: 6-year ]
  • Acute coronary syndrome [ Time Frame: 6-year ]
  • Sustained ventricular tachycardia or ventricular fibrillation [ Time Frame: 6-year ]
  • Heart failure hospitalization [ Time Frame: 6-year ]
  • Stent thrombosis [ Time Frame: 6-year ]
    Stent thrombosis defined by Academic Research Consortium

  • Target-vessel revascularization [ Time Frame: 6-year ]
  • Clinically-driven target-lesion revascularization [ Time Frame: 6-year ]
  • Any coronary revascularization [ Time Frame: 6-year ]
  • Any clinically-driven coronary revascularization [ Time Frame: 6-year ]
  • Coronary artery bypass grafting [ Time Frame: 6-year ]
  • Stroke [ Time Frame: 6-year ]
    Any ischemic and hemorrhagic strokes excluding transient ischemic attacks

  • Worsening of angina due to coronary spasm [ Time Frame: 6-year ]
  • Bleeding complications [ Time Frame: 6-year ]
    Bleeding complications defined by GUSTO and TIMI definitions

  • Composite of death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any coronary revascularization [ Time Frame: 6-year ]
  • Composite of cardiac death, myocardial infarction, acute coronary syndrome, heart failure hospitalization [ Time Frame: 6-year ]
  • Composite of cardiovascular death, myocardial infarction, stroke [ Time Frame: 6-year ]

Enrollment: 801
Study Start Date: July 2010
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Beta-blocker
Use of Carvedilol with any dose
Drug: Carvedilol
Use of Carvedilol with any dose
Active Comparator: Non Beta-blocker
No use of Carvedilol
Drug: No Carvedilol
No use of Carvedilol

Detailed Description:
Beta-blocker therapy is recommended after ST-segment elevation acute myocardial infarction (STEMI) in the current guidelines although its efficacy in those patients who have undergone primary percutaneous coronary intervention (PCI) has not been adequately evaluated. The purpose of this study is to evaluate whether beta-blocker, carvedilol improves 6-year clinical outcomes in patients with STEMI and preserved left ventricular ejection fraction after primary PCI. The design of this study is multicenter, open-label, randomized controlled trial enrolling 1300 patients without any exclusion criteria.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with STEMI after primary PCI
  • Patients with left ventricular ejection fraction more than or equal to 40%

Exclusion Criteria:

  • Patients with left ventricular ejection fraction less than 40%
  • Patients with contraindication for beta-blocker
  • Patients with implantable cardioverter defibrillators
  • Patients with end-stage malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01155635

Locations
Japan
Division of Cardiology, Kyoto University Hospital
Kyoto, Japan, 606-8507
Sponsors and Collaborators
Takeshi Morimoto
Investigators
Principal Investigator: Takeshi Kimura, MD Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
  More Information

Responsible Party: Takeshi Morimoto, Professor, Kyoto University, Graduate School of Medicine
ClinicalTrials.gov Identifier: NCT01155635     History of Changes
Other Study ID Numbers: C-417
Study First Received: July 1, 2010
Last Updated: January 5, 2016

Keywords provided by Kyoto University, Graduate School of Medicine:
Myocardial infarction
Adrenergic beta-Antagonists
Percutaneous coronary intervention

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Carvedilol
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists

ClinicalTrials.gov processed this record on April 28, 2017